Novacyt S.A. - NIPT Tender Award

Novacyt SA

27/01/2026 07:00

RNS Number : 4258Q

Novacyt S.A.

27 January 2026

 

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

NIPT Tender Award

Contract signed with St George's University Hospitals NHS Foundation Trust

 

Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that its wholly owned subsidiary, Yourgene Health UK Ltd ("Yourgene") has been awarded the South West London Procurement Partnership tender for the provision of Non-Invasive Prenatal Testing ("NIPT") using Yourgene's flagship IONA® Nx NIPT Workflow (CE-IVD), for St George's University Hospitals NHS Foundation Trust, London ("St George's") following a competitive tender process.

 

Yourgene won its first contract with St George's on 23 March 2015 and since then, St George's has been using the IONA® Nx test under the St George's Antenatal Fetal Evaluation ("SAFE") brand. The SAFE test has been set up as a collaboration between the Fetal Medicine Unit and the St George's Genomics Service, which is a UKAS accredited medical laboratory. The service provides NIPT to approximately one third of the NHS (National Health Service) maternity services population in England and is also offered privately at St George's hospital.

 

The contract is for an initial two-year period from December 2025, with an option to extend for a further two years. This represents a continuation of existing business to the Company.

 

Yourgene's flagship IONA® Nx NIPT Workflow (CE-IVD) is an in vitro diagnostic device for prenatal screening which enables clinical laboratories to establish their own quality assured non-invasive prenatal screening service for Down's (Trisomy 21), Edwards' (Trisomy 18) and Patau's (Trisomy 13) syndromes, in line with UK National Screening Committee recommendations and NHS England requirements.

 

Lyn Rees, CEO of Novacyt, commented: "We are very pleased to have been awarded this contract following a competitive tender process and for St. George's continuing confidence in our capabilities. This win underpins the quality of our product and service in a market where we continue to deliver year on year double digit growth. As the sector expands and trade barriers ease, we are well-positioned to capture emerging opportunities and create long-term value. Our focus remains on operational excellence, innovation, and supporting our partners in delivering improved clinical and patient outcomes."

 

 

Contacts

 

Novacyt SA
https://novacyt.com/investors
Lyn Rees, Chief Executive Officer
Via Walbrook PR
Steve Gibson, Chief Financial Officer
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)
+44 (0)20 3470 0470
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Singer Capital Markets(Joint Broker)
+44 (0) 20 7496 3000
Phil Davies / James Fischer / Samed Ethemi
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10r.durgetto@allegrafinance.com/y.petit@allegrafinance.com
Walbrook PR (Financial PR & IR)
Paul McManus / Lianne Applegarth
Alice Woodings
+44 (0)20 7933 8780 ornovacyt@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7584 391 303
+44 (0)7407 804 654


 

About Novacyt Group (www.novacyt.com)

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

 

The Company is divided into three business segments:

 

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
· genesig q16 and q32 real-time quantitative PCR (qPCR) instruments
Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

 

Novacyt is headquartered in Le Vésinet in France with offices in the UK (Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
CNTEAKFKASKKEFA